BNP Paribas Financial Markets
OREX

BNP Paribas Financial Markets’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BNP Paribas Financial Markets’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,887
Closed -$32.5K – 3585
2015
Q4 		$32.5K Sell
1,887
-258
-12% -$6.15K ﹤0.01% 3081
2015
Q3 		$45.2K Sell
2,145
-206
-9% -$7.06K ﹤0.01% 2933
2015
Q2 		$116K Buy
2,351
+62
+3% +$3.71K ﹤0.01% 2000
2015
Q1 		$179K Buy
2,289
+1,039
+83% +$64.4K ﹤0.01% 1586
2014
Q4 		$75.8K Sell
1,250
-5,868
-82% -$295K ﹤0.01% 1589
2014
Q3 		$303K Buy
7,118
+4,600
+183% +$247K ﹤0.01% 1713
2014
Q2 		$156K Sell
2,518
-4,852
-66% -$282K ﹤0.01% 1880
2014
Q1 		$414K Buy
7,370
+7,247
+5,892% +$490K ﹤0.01% 1518
2013
Q4 		$6.91K Sell
123
-2,461
-95% -$138K ﹤0.01% 2891
2013
Q3 		$158K Sell
2,584
-822
-24% -$55.7K ﹤0.01% 2319
2013
Q2 		$199K Buy
+3,406
New +$210K ﹤0.01% 2337

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BNP Paribas Financial Markets's OREX Position: Q1 2016 in Review

BNP Paribas Financial Markets sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 1,887 shares — an estimated $32.5K sold.

BNP Paribas Financial Markets first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $414K in Q1 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • BNP Paribas Financial Markets reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,887 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $32.5K.
  • BNP Paribas Financial Markets first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • BNP Paribas Financial Markets's Orexigen Therapeutics, Inc. position peaked at $414K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2016, filed 22 Apr 2016.